Latest news and updates related to Lactose Intolerance. Subscribe
to get latest posts via email or subscribe to a RSS feed
Thursday, April 05, 2018 -- Dennis A. SavaianoRP-G28, a novel prebiotic in development for the treatment of lactose intolerance has the potential to become the first FDA-approved treatment for lactose intolerance, a condition that affects millions of Americans, according to the developer Ritter Pharmaceuticals.To learn more about its mechanism of action, the target patient population, and the late phase development program, Healio Gastroenterology and Liver Disease spoke with Ritter Pharmaceuticals’ medical advisory board member Dennis A. Savaiano, PhD, Meredith Professor in the department of nutrition science at
Tuesday, October 03, 2017 -- Los Angeles, California,, Oct. 03, 2017 -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a leading developer of novel therapeutic products that modulate the human gut...
Monday, August 07, 2017 -- RP-G28, a novel non-digestible oligosaccharide designed to stimulate the gut microbiota to metabolize lactose, significantly reduced symptoms in patients with lactose intolerance, according to a press release.Ritter Pharmaceuticals Inc. announced this additional finding from its phase 2b/3 trial study that researchers designed to assess the efficacy, safety and tolerability of 2 dosing regimens of RP-G28. The trial comprised 377 patients with lactose intolerance and included a 30-day course treatment phase and a 30-day post-treatment “real world” observation phase where patients had foods containing lactose reintroduced into their diets, per the press release.
Monday, August 07, 2017 -- NewsRitter Pharmaceuticals reports further analysis from its Phase 2b/3 trial results demonstrating significant reductions in lactose intolerance symptoms. Analysis shows clinically meaningful benefit from symptoms, global patient-reported, and real-world assessments.Contributed Author: Ritter Pharmaceuticals, Inc.Topics: Drug Development